Profile
icholas Sosiak joined Cannara Biotech as its CFO at a moment when the Canadian cannabis industry was completing its most brutal capital destruction cycle.
The post-legalization euphoria that had produced hundreds of public companies, billions in equity raises, and valuations disconnected from any plausible business model had exhausted itself. What remained were the operators with genuine infrastructure, genuine revenue, and the financial discipline to survive what the others could not.
Cannara Biotech is among that remainder. The Quebec-based cannabis producer built its operation around a facility in Farnham, Quebec that represents one of the most modern and efficient cannabis cultivation environments in the country.
That capital investment required the kind of financial conviction difficult to maintain when peers were raising at multiples that made operational discipline feel like a competitive disadvantage. The company's $100 million valuation reflects not the promise of a category but the reality of a business that was built correctly when most of its sector was not.
Sosiak's role in that story is the one least often told in the cannabis industry: the finance story.
The infrastructure of a serious cannabis company — the balance sheet management, the working capital discipline, the public company disclosure obligations, the relationship with institutional shareholders through multiple cycles of sector sentiment — is a discipline that most cannabis operators proved unable to maintain. Cannara maintained it because it hired for it.
In conversation on The Montreal Entrepreneur Podcast, Sosiak speaks with the particular clarity of a financial executive who has had to explain the same business in radically different market environments.
He has presented Cannara's story to investors when cannabis was the most exciting sector in the country and when it was among the least. The discipline required to hold a consistent strategic narrative across that range of external conditions is, he argues, the most important financial work a CFO can do.
His perspective on building a public company in an industry still working toward institutional legitimacy is among the more substantive finance conversations the archive has produced. The lessons are not specific to cannabis. They apply to any founder navigating the relationship between a capital-intensive operation and a market that does not yet fully understand it.
When everyone in your sector is raising at impossible multiples, the most contrarian thing you can do is build a real business. That's what Cannara did.
— Nicholas Sosiak
Key Takeaways
Financial discipline is a competitive advantage in capital-intensive industries — Cannara's decision to build operational infrastructure correctly, rather than raise and spend at sector multiples, is why it survived cycles that eliminated peers.
The CFO's most important function in a public company is maintaining a consistent strategic narrative across radically different market environments — investors who bought the story in euphoria need the same story to hold in contraction.
Cannabis legalization created a case study in what happens when a sector prices narrative rather than fundamentals — the post-2018 capital destruction eliminated most operators and left those with genuine business models.
Quebec's regulatory environment and Cannara's Farnham facility represent a competitive position that cannot be quickly replicated — durable advantages in cannabis are physical and operational, not financial.
Building institutional credibility in a sector without it requires a longer timeline and a more deliberate investor relations strategy than most founders anticipate — the market's perception of a category changes slowly and the work to change it cannot be delegated.
The CFO job in a public company is half finance and half translation — you have to make the same story legible to investors who are in completely different emotional states about your industry.
— Nicholas Sosiak
The operators who survived cannabis weren't the ones who raised the most. They were the ones who spent it most carefully.
— Nicholas Sosiak
About Nicholas Sosiak
Nicholas Sosiak is the CFO of Cannara Biotech, a Quebec-based cannabis producer operating from a state-of-the-art cultivation facility in Farnham, Quebec. He joined Cannara as the Canadian cannabis sector was completing its most significant capital destruction cycle and has since helped guide the company to a $100 million valuation through disciplined financial management, institutional-grade disclosure practices, and a balance sheet strategy built for multi-cycle durability rather than sector-peak performance. He appeared on The Montreal Entrepreneur Podcast in Episode 38.
The Vault Dispatch
A monthly record of Montreal’s most consequential founders.
SubscribeOnce a month. No fluff.
More from The Vault
The Vault Dispatch
A monthly record of Montreal’s most consequential founders.
SubscribeOnce a month. No fluff.